huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas
Status:
Withdrawn
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
To assess the response rate of huC242-DM4 given as an intravenous infusion to patients with
metastatic or locally advanced gastric or gastroesophageal junction cancer.